← BackLEMAITRE VASCULAR INC · Surgical & Medical Instruments & ApparatusLMAT
Low riskNext report: Around Nov 5 (est.)
The short versionA high-quality, profitable business with steady sales. Institutions are adding.
Going well
- Profitable every year for 10 years
- Sales up 14% last year
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 3.4% to their holdings in the quarter ending June 2026 (168 bought, 146 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$84.24-0.2% that day
- Company value
- $1.9B
- Share price times all shares
- Price vs profit (P/E)
- 29.6x
- You pay about $30 for each $1 of yearly profit
- Price vs sales
- 7.3x
- Company value is 7.3 times a year of sales
- Dividend yield
- 0.9%
- Yearly dividend as a share of today's price
- Cash vs value
- 1%
- Cash as a share of company value
From LMAT's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$70.4M+9.6% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $262.4M, up 12% from the 12 months before. Over 5 years, sales grew about 14% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.15.8%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.23.1%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$81.3M
- MissShare count not growingNot diluting owners. Falling means buybacks.+3.4% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.71.5%
- Revenue
- $249.6M
- +13.5% vs prior year
- 5-year growth
- +14.0%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 12.89x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $70.4M
- +9.6% YoY
- EPS
- $0.74
- vs $0.60
- Op. margin
- 29.0%
- +3.9 pts
- Gross margin
- 72.1%
- +2.1 pts
- Free cash flow
- $13.7M
- Share count
- +7.2%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.2
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+3.4%Institutions added 3.4% to their holdings. 168 bought, 146 sold. 5 quarters of net buying in a row.
Shares held by institutions22.9M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+0.9%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
23MNext reportAround Nov 5 (est.)Estimated from the same quarter last year
- Results filedAug 4
- Results filedMay 5
- Results filedFeb 25
- Results filedNov 6, 2025
- Results filedAug 5, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.